

Opening Remarks

Michael A. Mussallem
Chairman and CEO



Edwards

Our Credo

Through our actions, we will become trusted partners with customers, colleagues, and patients – creating a community unified in its mission to improve the quality of life around the world. Our results will benefit customers, patients, employees and shareholders.

We will celebrate our successes, thrive on discovery, and continually expand our boundaries. We will act boldly, decisively, and with determination on behalf of people fighting cardiovascular disease.



At Edwards Lifesciences, we are dedicated to providing innovative solutions for people fighting cardiovascular disease.

Helping Patients is Our Life's Work, and

life is now

Our Aspirations



Fostering an **inclusive culture** where all employees grow and thrive

Transforming patient lives with **breakthrough** medical technologies

Excelling as a **trusted partner** through distinguished quality and integrity

Passionate engagement that strengthens our communities

Delivering exceptional **shareholder value**

Helping Patients Around the World



Patient-Focused Innovation Strategy

Focus

Singular focus on the large unmet needs of structural heart and critically ill patients

Leadership

Lead groundbreaking standards of care through trusted relationships



Create
Meaningful
Value by
Transforming
Patient Care

Innovation

Pioneer breakthrough technologies with compelling evidence

Edwards' patient-focused innovation strategy has produced sustained underlying sales growth


Global Transcatheter Opportunity

\$10B⁺ by 2025

Focused on opportunities where **patient demand** is very large



Edwards Sales (*\$ in billions*)



Long-term investments have yielded high-value, organic growth

Track record of **triple wins**:

- Improved outcomes
- Enhanced quality of life
- Cost effectiveness

Edwards 2021 and Beyond



Edwards

2021 expected to be a year of significant growth and investment in our future

2021 Expectations

Mid-teens
Underlying net
sales growth

\$2.00 - \$2.20
Adjusted
EPS



TAVR

- Therapy expansion
- Technology advances
- Geographic expansion



Surgical

- Surgeon partnership
- Leading pipeline
- Growth segment focus



TMTT

- Differentiated portfolio
- Clinical evidence
- Real-world outcomes




Critical Care

- HemoSphere growth
- Smart technologies
- Portfolio expansion

2021 Product Group Milestones



EARLY TAVR Asymptomatic
Enrollment Completion



Japan TAVR
Low Risk Approval




INSPIRIS
China Launch




MITRIS
US and Japan Launch



Critical Care
Viewfinder
Connectivity
Solution



Alterra
Adaptive Prestent



Next Generation
PASCAL Delivery System
Initial Clinical Experience




Expanded
Launch
of KONECT



Launching
Moderate AS Trial



Next Generation
EVOQUE Mitral System
Initial Clinical Experience



SAPIEN X4
Clinical Trial Launch

2020 Investor Conference Agenda

Transcatheter Aortic Valve Replacement

Larry Wood and Huimin Wang, M.D.

Surgical Structural Heart

Daveen Chopra

Advanced Technologies

Todd Brinton, M.D.

**Transcatheter Mitral and
Tricuspid Therapies**

Bernard Zovighian and Jean-Luc Lemercier

Critical Care

Katie Szyman

Financial Outlook

Scott Ullem

Closing Remarks

Mike Mussallem

Question and Answer Session

Edwards' Executive Leadership Team



Michael Mussallem
Chairman & CEO



Donald Bobo, Jr.
Strategy & Corporate
Development



Todd Brinton, M.D.
Chief Scientific Officer



Daveen Chopra
Surgical Structural
Heart



Dirksen Lehman
Public Affairs



Jean-Luc Lemercier
EMEA, Canada
and Latin America



Christine McCauley
Human Resources



Gary Sorsher
Quality, Regulatory,
Clinical



Joseph Nuzzolese
Global Supply Chain



Arnold Pinkston
General Counsel



Katie Szyman
Critical Care



Scott Ullem
Chief Financial
Officer



Huimin Wang, M.D.
Japan, Asia and
Pacific



Larry Wood
Transcatheter Aortic
Valve Replacement



Bernard Zovighian
Transcatheter Mitral &
Tricuspid Therapies

Long-tenured expert
healthcare executives

Highly
strategic and
collaborative team

Incentives aligned with
shareholders



Edwards

Helping Patients is Our Life's Work, and

life is now